nach oben

Erschienen in:

19.11.2023 | Original Communication

The prognostic value of systematic genetic screening in amyotrophic lateral sclerosis patients

verfasst von: Di He, Yining Liu, Siqi Dong, Dongchao Shen, Xunzhe Yang, Meng Hao, Xianhong Yin, Xinyi He, Yi Li, Yi Wang, Mingsheng Liu, Jiucun Wang, Xiangjun Chen, Liying Cui

Erschienen in: Journal of Neurology | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with complex genetic architecture. Emerging evidence has indicated comorbidity between ALS and autoimmune conditions, suggesting a potential shared genetic basis. The objective of this study is to assess the prognostic value of systematic screening for rare deleterious mutations in genes associated with ALS and aberrant inflammatory responses.

Methods

A discovery cohort of 494 patients and a validation cohort of 69 patients were analyzed in this study, with population-matched healthy subjects (n = 4961) served as controls. Whole exome sequencing (WES) was performed to identify rare deleterious variants in 50 ALS genes and 1177 genes associated with abnormal inflammatory responses. Genotype–phenotype correlation was assessed, and an integrative prognostic model incorporating genetic and clinical factors was constructed.

Results

In the discovery cohort, 8.1% of patients carried confirmed ALS variants, and an additional 15.2% of patients carried novel ALS variants. Gene burden analysis revealed 303 immune-implicated genes with enriched rare variants, and 13.4% of patients harbored rare deleterious variants in these genes. Patients with ALS variants exhibited a more rapid disease progression (HR 2.87 [95% CI 2.03–4.07], p < 0.0001), while no significant effect was observed for immune-implicated variants. The nomogram model incorporating genetic and clinical information demonstrated improved accuracy in predicting disease outcomes (C-index, 0.749).

Conclusion

Our findings enhance the comprehension of the genetic basis of ALS within the Chinese population. It also appears that rare deleterious mutations occurring in immune-implicated genes exert minimal influence on the clinical trajectories of ALS patients.

Nur mit Berechtigung zugänglich

Swinnen B, Robberecht W (2014) The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol 10:661–670. https://doi.org/10.1038/nrneurol.2014.184CrossRefPubMed

Hardiman O, Al-Chalabi A, Chio A et al (2017) Amyotrophic lateral sclerosis. Nat Rev Dis Prim 3:17071. https://doi.org/10.1038/nrdp.2017.71CrossRefPubMed

Goutman SA, Hardiman O, Al-Chalabi A et al (2022) Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurol 21:480–493. https://doi.org/10.1016/S1474-4422(21)00465-8CrossRefPubMedPubMedCentral

Ying W (2023) Phenomic studies on diseases: potential and challenges. Phenomics 3:285–299. https://doi.org/10.1007/s43657-022-00089-4CrossRefPubMedPubMedCentral

Picard M (2022) Why do we care more about disease than health? Phenomics 2:145–155. https://doi.org/10.1007/s43657-021-00037-8CrossRefPubMedPubMedCentral

Goutman SA, Hardiman O, Al-Chalabi A et al (2022) Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurol 21:465–479. https://doi.org/10.1016/S1474-4422(21)00414-2CrossRefPubMedPubMedCentral

Al-Chalabi A, Hardiman O (2013) The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 9:617–628. https://doi.org/10.1038/nrneurol.2013.203CrossRefPubMed

He D, Cui L (2021) Assessing the causal role of selenium in amyotrophic lateral sclerosis: a mendelian randomization study. Front Genet 12:1–6. https://doi.org/10.3389/fgene.2021.724903ADSCrossRef

Liu B, Lyu L, Zhou W et al (2023) Associations of the circulating levels of cytokines with risk of amyotrophic lateral sclerosis : a Mendelian randomization study. BMC Med. https://doi.org/10.1186/s12916-023-02736-7CrossRefPubMedPubMedCentral

10.

Julian TH, Glascow N, Fisher AD et al (2021) Physical exercise is a risk factor for amyotrophic lateral sclerosis: convergent evidence from Mendelian randomisation, transcriptomics and risk genotypes. EBioMedicine 68:103397. https://doi.org/10.1016/j.ebiom.2021.103397CrossRefPubMedPubMedCentral

11.

Alipour P, Senkevich K, Ross JP et al (2022) Investigation of the causal relationship between ALS and autoimmune disorders : a Mendelian randomization study. BMC Med. https://doi.org/10.1186/s12916-022-02578-9CrossRefPubMedPubMedCentral

12.

Shepheard SR, Parker MD, Cooper-Knock J et al (2021) Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2020-325014CrossRefPubMed

13.

Opie-Martin S, Iacoangeli A, Topp SD et al (2022) The SOD1-mediated ALS phenotype shows a decoupling between age of symptom onset and disease duration. Nat Commun 13:1–9. https://doi.org/10.1038/s41467-022-34620-yCrossRef

14.

Dong S, Yin X, Wang K et al (2023) Presence of rare variants is associated with poorer survival in chinese patients with amyotrophic lateral sclerosis. Phenomics 3:167–181. https://doi.org/10.1007/s43657-022-00093-8CrossRefPubMed

15.

Chio A, Moglia C, Canosa A et al (2023) Association of copresence of pathogenic variants related to amyotrophic lateral sclerosis and prognosis. Neurology. https://doi.org/10.1212/WNL.0000000000207367.10.1212/WNL.0000000000207367CrossRefPubMedPubMedCentral

16.

Chia R, Chiò A, Traynor BJ (2018) Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol 17:94–102. https://doi.org/10.1016/S1474-4422(17)30401-5CrossRefPubMed

17.

Saez-Atienzar S, Bandres-Ciga S, Langston RG et al (2021) Genetic analysis of amyotrophic lateral sclerosis identifies contributing pathways and cell types. Sci Adv 7:1–14. https://doi.org/10.1126/sciadv.abd9036CrossRef

18.

Feldman EL, Goutman SA, Petri S et al (2022) Amyotrophic lateral sclerosis. Lancet 400:1363–1380. https://doi.org/10.1016/S0140-6736(22)01272-7CrossRefPubMedPubMedCentral

19.

Coque E, Salsac C, Espinosa-Carrasco G et al (2019) Cytotoxic CD8 + T lymphocytes expressing ALS-causing SOD1 mutant selectively trigger death of spinal motoneurons. Proc Natl Acad Sci U S A 116:2312–2317. https://doi.org/10.1073/pnas.1815961116ADSCrossRefPubMedPubMedCentral

20.

Yu CH, Davidson S, Harapas CR et al (2020) TDP-43 triggers mitochondrial DNA release via mPTP to activate cGAS/STING in ALS. Cell 183:636-649.e18. https://doi.org/10.1016/j.cell.2020.09.020CrossRefPubMedPubMedCentral

21.

McCauley ME, O’Rourke JG, Yáñez A et al (2020) C9orf72 in myeloid cells suppresses STING-induced inflammation. Nature 585:96–101. https://doi.org/10.1038/s41586-020-2625-xADSCrossRefPubMedPubMedCentral

22.

Wei Q, Chen Y, Chen X et al (2018) Prognostic nomogram associated with longer survival in amyotrophic lateral sclerosis patients. Aging Dis. 9:965. https://doi.org/10.14336/AD.2017.1016CrossRefPubMedPubMedCentral

23.

Liu L, Zhu S (2021) computational methods for prediction of human protein-phenotype associations: a review. Phenomics 1:171–185. https://doi.org/10.1007/s43657-021-00019-wCrossRefPubMedPubMedCentral

24.

Westeneng HJ, Debray TPA, Visser AE et al (2018) Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol 17:423–433. https://doi.org/10.1016/S1474-4422(18)30089-9CrossRefPubMed

25.

Shen D, Cui B, Liu M et al (2020) Strategy for screening cognitive impairment in Chinese patients with amyotrophic lateral sclerosis. J Clin Neurosci 81:105–110. https://doi.org/10.1016/j.jocn.2020.09.016CrossRefPubMed

26.

Hao M, Pu W, Li Y et al (2021) The HuaBiao project: whole-exome sequencing of 5000 Han Chinese individuals. J Genet Genomics 48:1032–1035. https://doi.org/10.1016/j.jgg.2021.07.013CrossRefPubMed

27.

He D, Shang L, Liu Q et al (2021) Association of apolipoprotein E ε4 allele and amyotrophic lateral sclerosis in Chinese population. Amyotroph Lateral Scler Front Degener. https://doi.org/10.1080/21678421.2021.1953077CrossRef

28.

Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405–424. https://doi.org/10.1038/gim.2015.30CrossRefPubMedPubMedCentral

29.

Li Q, Wang K (2017) InterVar: clinical interpretation of genetic variants by the 2015 ACMG-AMP guidelines. Am J Hum Genet 100:267–280. https://doi.org/10.1016/j.ajhg.2017.01.004CrossRefPubMedPubMedCentral

30.

Jagadeesh KA, Wenger AM, Berger MJ et al (2016) M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity. Nat Genet 48:1581–1586. https://doi.org/10.1038/ng.3703CrossRefPubMed

31.

Schwarz JM, Cooper DN, Schuelke M, Seelow D (2014) Mutationtaster2: mutation prediction for the deep-sequencing age. Nat Methods 11:361–362. https://doi.org/10.1038/nmeth.2890CrossRefPubMed

32.

Ioannidis NM, Rothstein JH, Pejaver V et al (2016) REVEL: an ensemble method for predicting the pathogenicity of rare missense variants. Am J Hum Genet 99:877–885. https://doi.org/10.1016/j.ajhg.2016.08.016CrossRefPubMedPubMedCentral

33.

Glass JD, Dewan R, Ding J et al (2022) ATXN2 intermediate expansions in amyotrophic lateral sclerosis. Brain 145:2671–2676. https://doi.org/10.1093/brain/awac167CrossRefPubMedPubMedCentral

34.

Wu MC, Lee S, Cai T et al (2011) Rare-variant association testing for sequencing data with the sequence kernel association test. Am J Hum Genet 89:82–93. https://doi.org/10.1016/j.ajhg.2011.05.029CrossRefPubMedPubMedCentral

35.

Chen YP, Yu SH, Wei QQ et al (2022) Role of genetics in amyotrophic lateral sclerosis: a large cohort study in Chinese mainland population. J Med Genet 59:840–849. https://doi.org/10.1136/jmedgenet-2021-107965CrossRefPubMed

36.

Chen W, Xie Y, Zheng M et al (2020) Clinical and genetic features of patients with amyotrophic lateral sclerosis in southern China. Eur J Neurol 27:1017–1022. https://doi.org/10.1111/ene.14213CrossRefPubMed

37.

Liu ZJ, Lin HX, Wei Q et al (2019) Genetic spectrum and variability in Chinese patients with amyotrophic lateral sclerosis. Aging Dis. 10:1199–1206. https://doi.org/10.14336/AD.2019.0215CrossRefPubMedPubMedCentral

38.

Van Rheenen W, Shatunov A, Dekker AM et al (2016) Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat Genet 48:1043–1048. https://doi.org/10.1038/ng.3622CrossRefPubMedPubMedCentral

39.

Kim G, Gautier O, Tassoni-Tsuchida E et al (2020) ALS genetics: gains, losses, and implications for future therapies. Neuron. https://doi.org/10.1016/j.neuron.2020.08.022CrossRefPubMedPubMedCentral

40.

van Es MA, Hardiman O, Chio A et al (2017) Amyotrophic lateral sclerosis. Lancet 390:2084–2098. https://doi.org/10.1016/S0140-6736(17)31287-4CrossRefPubMed

41.

Grassano M, Calvo A, Moglia C et al (2021) Mutational analysis of known ALS genes in an Italian population-based cohort. Neurology 96:e600–e609. https://doi.org/10.1212/WNL.0000000000011209CrossRefPubMedPubMedCentral

42.

Grassano M, Calvo A, Moglia C et al (2022) Systematic evaluation of genetic mutations in ALS: A population-based study. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2022-328931CrossRefPubMed

43.

McCann EP, Henden L, Fifita JA et al (2021) Evidence for polygenic and oligogenic basis of Australian sporadic amyotrophic lateral sclerosis. J Med Genet 58:87–95. https://doi.org/10.1136/jmedgenet-2020-106866CrossRef

44.

Al-Chalabi A, Calvo A, Chio A et al (2014) Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol 13:1108–1113. https://doi.org/10.1016/S1474-4422(14)70219-4CrossRefPubMedPubMedCentral

45.

Li C, Ji Y, Tang L et al (2015) Optineurin mutations in patients with sporadic amyotrophic lateral sclerosis in China. Amyotroph Lateral Scler Front Degener 16:485–489. https://doi.org/10.3109/21678421.2015.1089909CrossRef

46.

Van Blitterswijk M, Van Es MA, Hennekam EAM et al (2012) Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Hum Mol Genet 21:3776–3784. https://doi.org/10.1093/hmg/dds199CrossRefPubMed

47.

Bali T, Self W, Liu J et al (2017) Defining SOD1 ALS natural history to guide therapeutic clinical trial design. J Neurol Neurosurg Psychiatry 88:99–105. https://doi.org/10.1136/jnnp-2016-313521CrossRefPubMed

48.

Mccauley ME, Baloh RH (2019) Inflammation in ALS/FTD pathogenesis. Acta Neuropathol 137:715–730. https://doi.org/10.1007/s00401-018-1933-9CrossRefPubMed

49.

He D, Xu Y, Liu M, Cui L (2023) The inflammatory puzzle: piecing together the links between neuroinflammation and amyotrophic lateral sclerosis. Aging Dis. https://doi.org/10.14336/AD.2023.0519CrossRefPubMedPubMedCentral

50.

Beers DR, Zhao W, Wang J et al (2017) ALS patients’ regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight 2:1–14. https://doi.org/10.1172/jci.insight.89530CrossRef

51.

Murdock BJ, Zhou T, Kashlan SR et al (2017) Correlation of peripheral immunity with rapid amyotrophic lateral sclerosis progression. JAMA Neurol 74:1446. https://doi.org/10.1001/jamaneurol.2017.2255CrossRefPubMedPubMedCentral

52.

Turner MR, Goldacre R, Ramagopalan S et al (2013) Autoimmune disease preceding amyotrophic lateral sclerosis: an epidemiologic study. Neurology 81:1222–1225. https://doi.org/10.1212/WNL.0b013e3182a6cc13CrossRefPubMedPubMedCentral

53.

Chiot A, Zaïdi S, Iltis C et al (2020) Modifying macrophages at the periphery has the capacity to change microglial reactivity and to extend ALS survival. Nat Neurosci 23:1339–1351. https://doi.org/10.1038/s41593-020-00718-zCrossRefPubMed

54.

Sheean RK, McKay FC, Cretney E et al (2018) Association of regulatory T-Cell expansion with progression of amyotrophic lateral sclerosis a study of humans and a transgenic mouse model. JAMA Neurol 75:681–689. https://doi.org/10.1001/jamaneurol.2018.0035CrossRefPubMedPubMedCentral

55.

Fournier CN, Bedlack R, Quinn C et al (2020) Development and validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS). JAMA Neurol 77:480–488. https://doi.org/10.1001/jamaneurol.2019.4490CrossRefPubMed

56.

Roche JC, Rojas-Garcia R, Scott KM et al (2012) A proposed staging system for amyotrophic lateral sclerosis. Brain 135:847–852. https://doi.org/10.1093/brain/awr351CrossRefPubMedPubMedCentral

57.

Chiò A, Hammond ER, Mora G et al (2015) Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 86:38–44. https://doi.org/10.1136/jnnp-2013-306589CrossRefPubMed

58.

Rooney J, Burke T, Vajda A et al (2017) What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 88:381–385. https://doi.org/10.1136/jnnp-2016-314661CrossRefPubMed

59.

Lek M, Karczewski KJ, Minikel EV et al (2016) Analysis of protein-coding genetic variation in 60,706 humans. Nature 536:285–291. https://doi.org/10.1038/nature19057CrossRefPubMedPubMedCentral

Titel: The prognostic value of systematic genetic screening in amyotrophic lateral sclerosis patients
verfasst von: Di He
Yining Liu
Siqi Dong
Dongchao Shen
Xunzhe Yang
Meng Hao
Xianhong Yin
Xinyi He
Yi Li
Yi Wang
Mingsheng Liu
Jiucun Wang
Xiangjun Chen
Liying Cui
Publikationsdatum: 19.11.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 3/2024
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-023-12079-1

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Demenz Nachrichten

Der Einsatz von Antipsychotika gegen psychische und Verhaltenssymptome in Zusammenhang mit Demenzerkrankungen erfordert eine sorgfältige Nutzen-Risiken-Abwägung. Neuen Erkenntnissen zufolge sind auf der Risikoseite weitere schwerwiegende Ereignisse zu berücksichtigen.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2024

Clinical and functional characteristics, possible causes, and impact of chronic cough in patients with cerebellar ataxia, neuropathy, and bilateral vestibular areflexia syndrome (CANVAS)

Unveiling the SOD1-mediated ALS phenotype: insights from a comprehensive meta-analysis

Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry

Macro- and micro-structural insights into primary dystonia: a UK Biobank study

Efficacy of the use of video games on mood, anxiety and depression in stroke patients: preliminary findings of a randomised controlled trial